Summary
Edwards Lifesciences Corporation reported solid revenue growth in the third quarter and first nine months of 2010, driven primarily by its Heart Valve Therapy segment. Net sales increased by 7.1% in Q3 and 8.2% year-to-date, with international markets showing particularly strong performance. The company also saw improvements in gross profit margin, reflecting a favorable product mix and operational efficiencies. Despite overall positive financial trends, the company recorded special charges in the current period, notably an $8.3 million charge related to the discontinuation of its MONARC transcatheter mitral valve program, and a $3.9 million investment impairment. These items impacted net income, which saw a decline compared to the prior year's comparable periods, partly due to these charges and the absence of significant one-time gains seen in 2009. The company continues to invest heavily in Research and Development, particularly in its transcatheter heart valve technologies, anticipating future growth from these initiatives.
Financial Highlights
47 data points| Revenue | $348.90M |
| Cost of Revenue | $95.80M |
| Gross Profit | $253.10M |
| R&D Expenses | $52.70M |
| SG&A Expenses | $133.00M |
| Net Income | $48.00M |
| EPS (Basic) | $0.07 |
| EPS (Diluted) | $0.07 |
| Shares Outstanding (Basic) | 681.60M |
| Shares Outstanding (Diluted) | 713.40M |
Key Highlights
- 1Net sales grew by 7.1% to $348.9 million in Q3 2010 and by 8.2% to $1,054.6 million in the first nine months of 2010, driven by strong performance in Heart Valve Therapy and international markets.
- 2Gross profit margin improved to 72.5% in Q3 2010 and 72.0% for the nine-month period, up from 69.8% and 69.5% respectively in the prior year, indicating improved operational efficiency and product mix.
- 3The Heart Valve Therapy segment was a key growth driver, with sales up 15.2% in Q3 and 16.2% year-to-date, largely due to the Edwards SAPIEN transcatheter heart valve and new product introductions.
- 4Research and Development expenses increased by 18% in Q3 and 17% year-to-date, reflecting continued strategic investment in new technologies, particularly the transcatheter heart valve program.
- 5The company recorded $12.2 million in Special Charges (net) for the nine months ended September 30, 2010, including an $8.3 million charge for the discontinuation of the MONARC program and a $3.9 million investment impairment.
- 6Diluted earnings per share decreased to $0.40 in Q3 2010 and $1.29 year-to-date, compared to $0.63 and $1.55 in the prior year, impacted by special charges and the absence of significant gains recorded in 2009.
- 7The company had $361.0 million in cash and cash equivalents as of September 30, 2010, and demonstrated positive cash flow from operations of $157.4 million for the first nine months of the year.